Crossmark

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis

Published Online: 2021-08-31

Published Print: 2021-12

Authors

Hirose, Wataru http://orcid.org/0000-0001-9095-6951
Harigai, Masayoshi

Amano, Koichi

Hidaka, Toshihiko

Itoh, Kenji

Aoki, Kazutoshi

Nakashima, Masahiro

Nagasawa, Hayato

Komano, Yukiko

Nanki, Toshihiro

,

Akiyama, Yuji

Ando, Souichirou

Hashiba, Yayoi

Kaneko, Motohide

Kawagoe, Mitsuhiro

Kondo, Tsuneo

Kubo, Kazuyoshi

Masuda, Ikuko

Matsumoto, Mitsuyo

Okada, Yusuke

Shibata, Akiko

Suzuki, Kimihiro

Takamatsu, Ko

Takei, Hirofumi
License Information

Text and Data Mining valid from 2021-08-31

Version of Record valid from 2021-08-31
More Information

Article History

Received: 14 December 2020

Accepted: 20 August 2021

First Online: 31 August 2021

Declarations

:

: The present study was performed in accordance with the Helsinki Declaration and was approved by the Ethics Committee of Toho University School of Medicine (approval number A17085). All participants gave their written informed consent.

: Not applicable.

Document is current